

A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma

Running title: Targeted therapy in DIPG

Fatma E. El-Khouly ^{1,2*}, Sophie E.M. Veldhuijzen van Zanten ^{1,2,3*}, Marc H.A. Jansen ^{1,4}, Dewi P. Bakker ⁵, Esther Sanchez Aliaga ⁶, N. Harry Hendrikse ^{6,7}, W. Peter Vandertop ⁸, Dannis G. van Vuurden ^{1,2#}, Gertjan J.L. Kaspers ^{1,2#}

¹ Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit Amsterdam, Pediatric Oncology, Amsterdam, The Netherlands

² Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

³ Erasmus MC, Radiology & Nuclear Medicine, Rotterdam, The Netherlands

⁴ Wilhelmina Children's Hospital, University Medical Center Utrecht, Immunology, Utrecht, the Netherlands

⁵ Emma Children's Hospital, Amsterdam UMC, Child Neurology, Amsterdam, The Netherlands

⁶ Amsterdam UMC, Vrije Universiteit Amsterdam, Radiology & Nuclear Medicine, Amsterdam, The Netherlands

⁷ Amsterdam UMC, Vrije Universiteit Amsterdam, Clinical Pharmacology & Pharmacy, Amsterdam, The Netherlands

⁸ Amsterdam UMC, Neurosurgical Center Amsterdam, Amsterdam, the Netherlands

* Shared first authorship

Shared last authorship

CORRESPONDING AUTHOR

Fatma E. El-Khouly

Amsterdam UMC, location VUmc - Pediatric Oncology

De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands

Tel.: +31 20 4445056

Email: f.el-khouly@amsterdamumc.nl

Supplementary Table 1: Complete radiologic response assessment of DIPG patients by a neuro-radiologist.

Patient ID	Week	Extension	Pontine involvement (%)	T2 hypointensity (%)	Encasement (°)	Metastasis	Diffusion restriction (%)	Heterogeneity	Hemorrhage	Enhancement extent (%)	Ring-like enhancement	Necrosis (%)	Perfusion	Hyper perfusion extent (%)	Hydrocephalus	Response (RANO)
1	Diagnosis	sup/post	>67	1-33	181-360	no	1-33	marked	none	67-100	yes	67-100	n.a.	n.a.	yes	n.a.
	Start study	sup	>67	1-33	0-180	no	none	mild	minimal	34-66	yes	34-66	hyper	34-66	no	n.a.
	Week 9	sup	>67	1-33	0-180	no	1-33	marked	minimal	34-66	yes	1-33	hyper	34-66	no	PD
2	Diagnosis	sup/post/inf	>67	none	181-360	no	none	marked	none	1-33	yes	1-33	hyper	34-66	no	n.a.
	Start study	sup/post/inf	>67	1-33	181-360	no	none	marked	none	34-66	yes	1-33	n.a.	n.a.	yes	n.a.
	Week 9	post	51-66	none	none	no	none	mild	minimal	1-33	yes	1-33	normal	n.a.	no	PR
	Week 17	sup/post/inf	>67	none	none	no	none	mild	none	1-33	yes	1-33	normal	n.a.	no	SD
3	Week 47	sup/post/inf	51-66	none	none	no	none	mild	none	1-33	yes	1-33	n.a.	n.a.	no	PD
	Diagnosis	sup/post/inf	>67	1-33	181-360	no	1-33	mild	spotty/minimal	1-33	yes	1-33	normal	n.a.	No	n.a.
	Start study	sup/post/inf	>67	none	0-180	no	none	marked	spotty/minimal	1-33	yes	1-33	n.a.	n.a.	yes	n.a.
4	Week 9	sup/post/inf	>67	1-33	181-360	no	1-33	marked	spotty/minimal	1-33	no	none	n.a.	n.a.	yes	PD
	Diagnosis	post	>67	1-33	181-360	no	n.a.	marked	none	1-33	yes	1-33	n.a.	n.a.	no	n.a.
	Start study	post	>67	1-33	0-180	no	1-33	marked	none	67-100	yes	67-100	n.a.	n.a.	no	n.a.
	Week 9	post	>67	1-33	0-180	no	1-33	marked	none	67-100	yes	1-33	hyper	1-33	no	PR
5	Week 17	sup/post	>67	1-33	0-180	no	1-33	marked	spotty/minimal	1-33	yes	1-33	normal	n.a.	no	PD
	Diagnosis	sup/post/inf	>67	none	181-360	no	none	mild	none	1-33	no	n.a.	hyper	1-33	no	n.a.
	Start study	sup/post/inf	>67	none	181-360	no	1-33	mild	none	34-66	yes	1-33	n.a.	n.a.	no	n.a.
	Week 9	sup/post/inf	>67	none	181-360	no	none	mild	none	1-33	no	none	none	n.a.	no	SD
6	Week 17	sup/post/inf	>67	none	181-360	no	none	moderate	none	34-66	no	none	n.a.	n.a.	no	PD
	Diagnosis	sup/post/inf	100	1-33	full	no	none	mild	no	1-33	no	none	hyper	10	no	n.a.
	Start study	sup/post/inf	100	none	full	no	none	mild	no	1-33	no	none	n.a.	n.a.	yes	n.a.
	Week 9	sup/post/inf	100	none	full	no	n.a.	mild	no	1-33	no	none	n.a.	n.a.	yes	PD
7	Diagnosis	sup/post	>67	34-66	181-360	no	none	marked	yes	1-33	yes	none	n.a.	n.a.	yes	n.a.
	Start study	sup/post/inf	>67	1-33	full	no	none	marked	none	34-66	yes	34-66	n.a.	n.a.	yes	n.a.
	Week 9	sup/post/inf	>67	1-33	full	yes	1-33	marked	none	34-66	yes	34-66	n.a.	n.a.	yes	PD
8	Diagnosis	post	>67	none	181-360	no	none	mild	none	none	no	none	n.a.	n.a.	no	n.a.
	Start study	sup/post/inf	>67	none	181-360	no	none	marked	none	34-66	yes	34-66	n.a.	n.a.	yes	n.a.
	Week 9	post/inf	>67	none	181-360	no	none	moderate	none	1-33	yes	1-33	n.a.	n.a.	no	PR
	Week 17	post/inf	>67	none	181-360	no	none	moderate	none	1-33	yes	1-33	n.a.	n.a.	no	SD
9	Diagnosis	inf	>67	1-33	181-360	no	none	mild	none	none	no	none	n.a.	n.a.	no	n.a.
	Start study	sup/inf	>67	1-33	181-360	no	1-33	mild	none	none	no	none	normal	n.a.	no	n.a.
	Week 9	sup/post/inf	>67	1-33	full	no	none	moderate	none	1-33	no	none	n.a.	n.a.	yes	PD

Sup: superior (midbrain, thalami); post: posterior (cerebellum, brachium pontis); inf: inferior (medulla); PD: progressive disease; PR: partial response; SD: stable disease; n.a.: not applicable